AXIM Biotechnologies Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
AXIM
- Investments
-
1
AXIM Biotechnologies General Information
Description
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Contact Information
Website
www.aximbiotech.comCorporate Office
- 45 Rockefeller Plaza
- 20th Floor
- New York, NY 10111
- United States
Corporate Office
- 45 Rockefeller Plaza
- 20th Floor
- New York, NY 10111
- United States
AXIM Biotechnologies Stock Performance
As of 13-Nov-2026, AXIM Biotechnologies’s current market cap is $1.1M with 350M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.1M | 350M | 237K |
AXIM Biotechnologies Financials Summary
As of 30-Jun-2025, AXIM Biotechnologies has a trailing 12-month revenue of $53K.
|
In Thousands, USD |
TTM 30-Jun-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 9,380 | 7,352 | 10,305 | 10,612 |
| Revenue | 53 | 70 | 40 | 9 |
| EBITDA | (201) | (2,452) | (6,428) | (3,941) |
| Net Income | (1,115) | (3,520) | (8,060) | (6,243) |
| Total Assets | 3,224 | 3,447 | 4,122 | 4,212 |
| Total Debt | 7,545 | 7,182 | 5,895 | 5,665 |
AXIM Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AXIM Biotechnologies Comparisons
Industry
Financing
Details
AXIM Biotechnologies Competitors (20)
One of AXIM Biotechnologies’s 20 competitors is Dermavant Sciences, a Formerly PE-Backed company based in Long Beach, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dermavant Sciences | Formerly PE-Backed | Long Beach, CA | ||||
| Aprecia | Formerly VC-backed | Mason, OH | ||||
| Cipla | Corporation | Mumbai, India | ||||
| AskBio | Formerly VC-backed | Durham, NC | ||||
| Aquapharm Biodiscovery | Formerly VC-backed | Oban, United Kingdom |
AXIM Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AXIM Biotechnologies Patents
AXIM Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220047017-A1 | Face masks and other protective devices having enhanced virus entrapment efficiency, and related methods | Inactive | 14-Aug-2020 | ||
| WO-2022036262-A1 | Face masks and other protective devices having enhanced virus entrapment efficiency, and related methods | Inactive | 14-Aug-2020 | ||
| US-11542226-B2 | Polyfunctional cannabinoids | Active | 23-Apr-2020 | ||
| US-20210332004-A1 | Polyfunctional cannabinoids | Active | 23-Apr-2020 | ||
| US-10913367-B2 | Charge and discharge management device | Active | 24-Aug-2017 | B60L55/00 |
AXIM Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AXIM Biotechnologies Acquisitions (1)
AXIM Biotechnologies’s most recent deal was a Merger/Acquisition with Sapphire Biotech for . The deal was made on 17-Mar-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sapphire Biotech | 17-Mar-2020 | Merger/Acquisition | Diagnostic Equipment |
AXIM Biotechnologies ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Facilities Maintenance
Subindustry
Rank
Percentile
AXIM Biotechnologies FAQs
-
When was AXIM Biotechnologies founded?
AXIM Biotechnologies was founded in 2010.
-
Where is AXIM Biotechnologies headquartered?
AXIM Biotechnologies is headquartered in New York, NY.
-
What is the size of AXIM Biotechnologies?
AXIM Biotechnologies has 7 total employees.
-
What industry is AXIM Biotechnologies in?
AXIM Biotechnologies’s primary industry is Pharmaceuticals.
-
Is AXIM Biotechnologies a private or public company?
AXIM Biotechnologies is a Public company.
-
What is AXIM Biotechnologies’s stock symbol?
The ticker symbol for AXIM Biotechnologies is AXIM.
-
What is the current market cap of AXIM Biotechnologies?
The current market capitalization of AXIM Biotechnologies is $1.1M.
-
What is AXIM Biotechnologies’s current revenue?
The trailing twelve month revenue for AXIM Biotechnologies is $53K.
-
Who are AXIM Biotechnologies’s competitors?
Dermavant Sciences, Aprecia, Cipla, AskBio, and Aquapharm Biodiscovery are some of the 20 competitors of AXIM Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
